Singapore markets closed

Eli Lilly and Company (LLY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
301.40+2.02 (+0.67%)
At close: 04:03PM EDT
302.00 +0.60 (+0.20%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close299.38
Bid285.00 x 800
Ask303.69 x 1000
Day's range293.39 - 303.40
52-week range193.11 - 314.00
Avg. volume2,967,843
Market cap286.378B
Beta (5Y monthly)0.43
PE ratio (TTM)44.80
EPS (TTM)6.73
Earnings date04 Aug 2022
Forward dividend & yield3.92 (1.34%)
Ex-dividend date13 May 2022
1y target est304.28
  • Motley Fool

    Why Eli Lilly Stock Climbed Today

    Shares of Eli Lilly (NYSE: LLY) rose on Monday after the U.S. Food and Drug Administration (FDA) approved the pharmaceutical giant's new diabetes treatment, tirzepatide. As of 1:50 p.m. ET, Eli Lilly's stock price was up more than 3%. A phase 3 clinical trial showed tirzepatide to reduce A1C -- a key measure of average blood sugar levels -- better than existing treatment options.

  • Zacks

    Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod

    Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.

  • Zacks

    Pharma Stock Roundup: PFE's Biohaven Buyout Offer, BAYRY's Q1 Earnings Update

    Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.